Current Impact and Application of Abuse-Deterrent Opioid Formulations in Clinical Practice

被引:1
|
作者
Lee, Ya-Han [1 ]
Brown, Daniel L. [2 ]
Chen, Hsiang-Yin [1 ,3 ]
机构
[1] Taipei Med Univ, Sch Pharm, Dept Clin Pharm, 250 Wu Hsin St, Taipei, Taiwan
[2] Calif Hlth Sci Univ, Coll Pharm, Clovis, CA USA
[3] Taipei Med Univ, Wan Fang Hosp, Dept Pharm, Taipei, Taiwan
关键词
Opioid abuse; abuse-deterrent formulations; ADF; post-marketing; FDA guidance; cost impact; abuse liking; physician attitude; generic abuse-deterrent formulation; clinical application; TAMPER-RESISTANT FORMULATIONS; EXTENDED-RELEASE HYDROCODONE; UNITED-STATES; CHRONIC PAIN; DOUBLE-BLIND; POSTOPERATIVE PAIN; SUBSTANCE-ABUSE; RISK-EVALUATION; NONMEDICAL USE; SINGLE-ENTITY;
D O I
暂无
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background: Abuse-deterrent formulations (ADFs) represent one novel strategy for curbing the potential of opioid abuse. Objective: We aim to compare and contrast the characteristics and applications of current abuse-deterrent opioid products in clinical practice. Methods: Literature searches were conducted in databases (Pubmed Medline, International Pharmaceutical Abstracts, Google Scholar) and official reports. Relevant data were screened and organized into: 1) epidemiology of opioid abuse, 2) mitigation strategies for reducing opioid abuse, 3) development of ADFs, and 4) clinical experience with these formulations. Results: Increasing trends of opioid abuse and misuse have been reported globally. There are 5 types of abuse-deterrent opioid products: physical chemical barrier, combined agonist/antagonist, sequestered aversive agent, prodrug, and novel delivery system. The advantages and disadvantages of the 5 options are discussed in this review. A total of 9 products with abuse-deterrent labels have been approved by the Food and Drug Administration (FDA). The rates of abuse, diversion, and overdose deaths of these new products are also discussed. A framework for collecting in-time data on the efficacy, benefit and risk ratio, and cost-effectiveness of these new products is suggested to facilitate their optimal use. Limitations: The present review did not utilize systematic review standards or meta-analytic techniques, given the large heterogeneity of data and outcomes reviewed. Conclusions: ADFs provide an option for inhibiting the abuse or misuse of oral opioid products by hindering extraction of the active ingredient, preventing alternative routes of administration, or causing aversion. Their relatively high costs, uncertain insurance policies, and limited data on pharmacoeconomics warrant collaborative monitoring and assessment by government agencies, pharmaceutical manufacturers, and data analysis services to define their therapeutic role in the future.
引用
收藏
页码:E1003 / E1023
页数:21
相关论文
共 50 条
  • [31] What's holding back abuse-deterrent opioid formulations? Considering 12 US stakeholders
    Pergolizzi, Joseph V., Jr.
    Taylor, Robert, Jr.
    LeQuang, Jo Ann
    Raffa, Robert B.
    EXPERT OPINION ON DRUG DELIVERY, 2018, 15 (06) : 567 - 576
  • [32] Development of Abuse-Deterrent Formulations Using Sucrose Acetate Isobutyrate
    Sogra F. Barakh Ali
    Sathish Dharani
    Hamideh Afrooz
    Eman M. Mohamed
    Phillip Cook
    Mansoor A. Khan
    Ziyaur Rahman
    AAPS PharmSciTech, 21
  • [33] A review on abuse-deterrent formulations: formulation technology and regulatory stands in approval process
    Bhola, Jaydip
    Borkhataria, Chetan
    PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, 2024, 29 (08) : 824 - 831
  • [34] Healthcare Resource Use and Cost: The Impact of Adopting an Abuse-Deterrent Formulation of Extended Release Morphine
    Rossiter, Louis F.
    Kwong, Winghan Jacqueline
    Marrett, Elizabeth
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2020, 12 : 35 - 44
  • [35] Development of Abuse-Deterrent Formulations Using Sucrose Acetate Isobutyrate
    Ali, Sogra F. Barakh
    Dharani, Sathish
    Afrooz, Hamideh
    Mohamed, Eman M.
    Cook, Phillip
    Khan, Mansoor A.
    Rahman, Ziyaur
    AAPS PHARMSCITECH, 2020, 21 (03)
  • [36] Kentucky pharmacists' experiences in dispensing abuse-deterrent opioid analgesics
    Oyler, Douglas R.
    Slavova, Svetla
    Brown, John R.
    Dasgupta, Nabarun
    Freeman, Patricia R.
    JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2022, 62 (06) : 1836 - 1842
  • [37] Evaluation of Abuse-Deterrent or Tamper-Resistant Opioid Formulations on Overall Health Care Expenditures in a State Medicaid Program
    Keast, Shellie L.
    Owora, Arthur
    Nesser, Nancy
    Farmer, Kevin
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2016, 22 (04) : 347 - 356
  • [38] Research design considerations for clinical studies of abuse-deterrent opioid analgesics: IMMPACT recommendations
    Turk, Dennis C.
    O'Connor, Alec B.
    Dworkin, Robert H.
    Chaudhry, Amina
    Katz, Nathaniel P.
    Adams, Edgar H.
    Brownstein, John S.
    Comer, Sandra D.
    Dart, Richard
    Dasgupta, Nabarun
    Denisco, Richard A.
    Klein, Michael
    Leiderman, Deborah B.
    Lubran, Robert
    Rappaport, Bob A.
    Zacny, James P.
    Ahdieh, Harry
    Burke, Laurie B.
    Cowan, Penney
    Jacobs, Petra
    Malamut, Richard
    Markman, John
    Michna, Edward
    Palmer, Pamela
    Peirce-Sandner, Sarah
    Potter, Jennifer S.
    Raja, Srinivasa N.
    Rauschkolb, Christine
    Roland, Carl L.
    Webster, Lynn R.
    Weiss, Roger D.
    Wolf, Kerry
    PAIN, 2012, 153 (10) : 1997 - 2008
  • [39] The Clinical Applications of Extended-Release Abuse-Deterrent Opioids
    Vadivelu, Nalini
    Schermer, Erika
    Kodumudi, Gopal
    Berger, Jack M.
    CNS DRUGS, 2016, 30 (07) : 637 - 646
  • [40] Anticipated and unanticipated consequences of abuse deterrent formulations of opioid analgesics
    Cicero, Theodore J.
    Ellis, Matthew S.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 (02) : 205 - 207